RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS

RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS

Show other versions (1)

(<em>Voprosy sovremennoi pediatrii = Current pediatrics</em>. 2008; 7(3):106-107)

Bibliographic Details
Main Author:	article editorial
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2008-01-01
Series:	Voprosy Sovremennoj Pediatrii
Online Access:	http://vsp.spr-journal.ru:80/jour/article/view/1408

Similar Items

RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS
by: article editorial
Published: (2008-06-01)

EXPERIMENTAL AND CLINICAL PHARMACOLOGY OF RIFAXIMIN SELECTIVE ENTERIC ANTIBIOTIC
by: article editorial
Published: (2008-05-01)

EXPERIMENTAL AND CLINICAL PHARMACOLOGY OF RIFAXIMIN SELECTIVE ENTERIC ANTIBIOTIC
by: article editorial
Published: (2008-05-01)

Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
by: E. Yu. Plotnikova
Published: (2021-05-01)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
by: Dominador Lao, et al.
Published: (2012-01-01)

Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico
by: O. Novoa-Farias, et al.
Published: (2017-07-01)

Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico
by: O. Novoa-Farías, et al.
Published: (2016-01-01)

Liver Fibrosis and Rifaximin
by: Ki Tae Suk
Published: (2017-11-01)

COMPLEX TREATMENT OF HELICOBACTER PYLORI INFECTION WITH RIFAXIMIN IN CHILDREN
by: A.A. Nizhevich, et al.
Published: (2009-11-01)

COMPLEX TREATMENT OF HELICOBACTER PYLORI INFECTION WITH RIFAXIMIN IN CHILDREN
by: A.A. Nizhevich, et al.
Published: (2009-01-01)

Rifaximin in the treatment of hepatic encephalopathy
by: Iadevaia MD, et al.
Published: (2011-12-01)

Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers
by: Blandizzi C, et al.
Published: (2014-12-01)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
by: George Tannous, et al.
Published: (2010-09-01)

Comparing efficacy of Rifaximin plus Lactulose vs. Lactulose alone in treating Hepatic Encephalopathy
by: Tanveer Hussain, et al.
Published: (2020-12-01)

Rifaximin Therapy of Irritable Bowel Syndrome
by: Hoonmo L. Koo, et al.
Published: (2012-01-01)

Rifaximin for Pertuzumab-Related GI Toxicities
by: Aixa E. Soyano, et al.
Published: (2017-08-01)

Rifaximin Therapy of Irritable Bowel Syndrome
by: Hoonmo L. Koo, et al.
Published: (2012-06-01)

Erratum: Shifrin O.S. et al., “Russian Non Interventional Study of the Efficacy and Tolerability of Rifaximin Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Practice”
by: article Editorial
Published: (2020-07-01)

Rifaximin as treatment for hepatic encephalopathy: Some considerations
by: Lorenzo Ridola, et al.
Published: (2013-01-01)

Rifaximin has the potential to prevent complications of cirrhosis
by: Steven L. Flamm, et al.
Published: (2018-09-01)

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
by: Lopez A Rocio, et al.
Published: (2008-06-01)

Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01)

The role of Rifaximine-α in traveler’s diarrhea therapy
by: Victoria Aramă, et al.
Published: (2016-03-01)

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial
by: P. Patrick Basu, et al.
Published: (2010-07-01)

Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Eradication
by: Hyun Soo Kim, et al.
Published: (2020-09-01)

Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
by: Kichul Yoon, et al.
Published: (2018-09-01)

Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy
by: C.E. Coronel-Castillo, et al.
Published: (2020-01-01)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
by: Kimer N, et al.
Published: (2014-03-01)

Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection
by: Paulina Konrad, et al.
Published: (2018-03-01)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin
by: Ana L. Sousa, et al.
Published: (2019-08-01)

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
by: Hafsa Habib, et al.
Published: (2016-12-01)

The role of rifaximin in the treatment and chemoprophylaxis of travelers&#39; diarrhea
by: Hoonmo L Koo, et al.
Published: (2009-10-01)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
by: Iorio N, et al.
Published: (2015-06-01)

Quantification of Rifaximin in Tablets by Spectrophotometric Method Ecofriendly in Ultraviolet Region
by: Ana Carolina Kogawa, et al.
Published: (2016-01-01)

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
by: Jasmohan S Bajaj, et al.
Published: (2013-01-01)

ECO-FRIENDLY AND MINIATURIZED ANALYTICAL METHOD FOR QUANTIFICATION OF RIFAXIMIN IN TABLETS
by: Clara Bersi Motta Correa, et al.
Published: (2019-12-01)

Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease
by: L. S. Оrеshkо, et al.
Published: (2019-10-01)

Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice
by: Marina Ferrer, et al.
Published: (2021-01-01)

Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model
by: Seung Kak Shin, et al.
Published: (2017-11-01)